Tseng Ching-Hung, Wong Sunny, Yu Jun, Lee Yeong Yeh, Terauchi Jun, Lai Hsin-Chih, Luo Jiing-Chyuan, Kao Cheng Yen, Yu Sung-Liang, Liou Jyh-Ming, Wu Deng-Chyang, Hou Ming-Chih, Wu Ming-Shiang, Wu Jiunn-Jong, Sung Joseph J Y, El-Omar Emad M, Wu Chun-Ying
Germark Biotechnology, Co, Ltd, Taichung, Taiwan.
Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
Gut. 2025 Apr 7;74(5):706-713. doi: 10.1136/gutjnl-2024-334501.
Live biotherapeutic products (LBPs) are biological products composed of living micro-organisms, developed to prevent, treat, or cure diseases. Examples include cultured strains of and , as well as treatments using purified Firmicutes spores for recurrent infections. There is a need for guidelines over the increasing interest in developing LBPs. A panel of microbiome experts from Asia-Pacific countries articulates their perspectives on key considerations for LBP development.
Experts in microbiome research, microbiology, gastroenterology, internal medicine and biotherapeutics industry were invited to form a panel. During the 2023 Inauguration Conference of the Asia-Pacific Microbiota Consortium, an organised, iterative roundtable discussion was conducted to build expert consensus on critical issues surrounding the development of LBP.
The consensus statements were organised into three main aspects: (a) rationales of LBP development, (b) preclinical studies and (c) preparation for clinical studies. The panel strongly recommended to prioritise human-derived and food-sourced strains for development, with indications based on clinical need and efficacy shown in studies. Preclinical evaluation should involve thorough screening, genotyping and phenotyping, as well as comprehensive in vitro and animal studies to assess functional mechanisms and microbiological safety. Rigorous cell banking practices and genetic monitoring are essential to ensure product consistency and safety throughout the manufacturing process. Clinical trials, including postmarketing surveillance, must be carefully designed and closely monitored, with robust safety and risk management protocols in place.
The development of LBP should be approached with a strong emphasis on microbiological evaluation, clinical relevance, scientific mechanisms and safety at every stage. These measures are essential to ensure the safety, effectiveness and long-term success of the product.
活体生物治疗产品(LBPs)是由活微生物组成的生物制品,旨在预防、治疗或治愈疾病。实例包括[具体微生物名称1]和[具体微生物名称2]的培养菌株,以及使用纯化的厚壁菌门孢子治疗复发性[感染类型]感染。鉴于对开发LBPs的兴趣日益增加,需要制定相关指南。来自亚太国家的一组微生物组专家阐述了他们对LBP开发关键考虑因素的看法。
邀请了微生物组研究、微生物学、胃肠病学、内科和生物治疗行业的专家组成一个小组。在2023年亚太微生物群联盟成立会议期间,组织了一场迭代式圆桌讨论,以就围绕LBP开发的关键问题达成专家共识。
共识声明分为三个主要方面:(a)LBP开发的基本原理,(b)临床前研究,以及(c)临床研究准备。该小组强烈建议优先开发源自人类和食物的菌株,并根据临床需求和研究中显示的疗效确定适应症。临床前评估应包括全面的筛选、基因分型和表型分析,以及全面的体外和动物研究,以评估功能机制和微生物安全性。严格的细胞库操作和基因监测对于确保整个生产过程中的产品一致性和安全性至关重要。临床试验,包括上市后监测,必须精心设计并密切监测,要有完善的安全和风险管理方案。
LBP的开发应在每个阶段都高度重视微生物评估、临床相关性、科学机制和安全性。这些措施对于确保产品的安全性、有效性和长期成功至关重要。